No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .
Beneficial Effects of Pentoxifylline in Patients With Idiopathic Dilated Cardiomyopathy Treated With Angiotensin-Converting Enzyme Inhibitors and Carvedilol: Results of a Randomized Study
Background —We previously reported beneficial effects of pentoxifylline , a xanthine-derived agent known to inhibit the production of tumor necrosis factor-&agr ; , in patients with idiopathic dilated cardiomyopathy treated with diuretics , digoxin , and ACE inhibitors .  Since then , 3 large clinical trials showed important clinical benefits of & bgr;-blockers in this population . Therefore , we design ed the present study to establish whether in patients with heart failure already receiving treatment with ACE inhibitors and & bgr;-blockers , the addition of pentoxifylline would have an additive beneficial effect . Methods and Results —In a single-center , prospect i ve , double-blind , r and omized , placebo-controlled study , 39 patients with idiopathic dilated cardiomyopathy were r and omized to pentoxifylline 400 mg TID ( n=20 ) or placebo ( n=19 ) if they had a left ventricular ejection fraction < 40 % after 3 months of therapy with digoxin , ACE inhibitors , and carvedilol . Primary end points were New York Heart Association functional class , exercise tolerance , and left ventricular function . Patients were followed up for 6 months . Five patients died ( 3 in the placebo group ) . Patients treated with pentoxifylline had a significant improvement in functional class compared with the placebo group ( P = 0.01 ) , with an increment in exercise time from 9.5±5 to 12.3±6 minutes ( P = 0.1 ) . Left ventricular ejection fraction improved from 24±9 % to 31±13 % , P = 0.03 , in the treatment group . Conclusions —In patients with idiopathic dilated cardiomyopathy , the addition of pentoxifylline to treatment with digoxin , ACE inhibitors , and carvedilol is associated with a significant improvement in symptoms and left ventricular function
No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .